Novo Nordisk A/S Sponsored ADR (NVO)
2 Dirt Cheap Healthcare Stocks to Buy in July
Healthcare has become Wall Street's bargain bin in 2026, and value hunters are starting to pay attention.
Novo Nordisk: The Stock Price Is Only Beginning To Catch Up With Business Fundamentals
Novo Nordisk (NVO) is rated a BUY as business fundamentals recover faster than the stock price, driven by oral Wegovy's historic U.S. launch. NVO's oral Wegovy is expanding the obesity market, with over 3 million U.S. prescriptions in five months and 80% from GLP-1–naïve patients. Management has raised 2026 guidance, citing stronger-than-expected GLP-1 sales and international growth, with further upward revisions likely.
Novo Nordisk (NVO) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Novo Nordisk (NVO) closed at $48.77, marking a +1.73% move from the previous day.
Medicare will start covering obesity drugs for the first time. Here's what patients should know
Starting Wednesday, eligible seniors with Medicare coverage can access GLP-1s for obesity with a copay of just $50 per month through a temporary program called Bridge. The move could unlock a vast new patient population for Novo Nordisk and Eli Lilly and dramatically expand access to medications that were previously out of reach for many older Americans.
Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?
NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
Novo's top US exec wants more insurance coverage for weight-loss drugs
Denmark's Novo Nordisk , the maker of weight-loss drug Wegovy, hopes insurance will cover more U.S. users of the medication and balance direct-to-consumer sales that have driven the fast-growing market, the company's top U.S. executive said.
NVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research Push
Novo Nordisk stock rises 6% after the launch of a EUR 60.2M foundation-backed initiative to speed cardiometabolic drug discovery and support Europe-wide innovation.
Novo Nordisk: The Selloff Looks Like A Gift, And I'm Buying
Novo Nordisk is upgraded to a 'Strong Buy' after a weak Q1 and significant stock price decline, presenting a compelling long-term entry point. NVO's GLP-1 portfolio, including Wegovy and Ozempic, faces near-term pricing headwinds but benefits from long-term tailwinds despite the upcoming 2027 price cuts. Strategic investments, aggressive R&D, and the Akero acquisition position NVO for the next stage of differentiation as the obesity market expands toward major opportunity.
Novo Nordisk's Wegovy pill headlines mask complicated competitive reality
Novo Nordisk's (NYSE:NVO) Wegovy pill is running three times ahead of rival Zepbound at the equivalent stage of launch, according to pharmacy data, a headline that implies dominant market positioning in oral GLP-1 therapeutics. But the data supporting that claim comes with substantial qualifications that tell a different story.
Can Wegovy Pill's Europe Push Help NVO Offset Mounting Pressures?
Wegovy pill's U.K. approval gives Novo Nordisk its first European launch path ahead of wider EU approval as it seeks growth amid mounting pricing and competitive pressures.
Hacking group claims major hack of Novo Nordisk and attempted $25 million extortion
A cyber extortion group claimed on Tuesday to have stolen more than a terabyte of data from pharmaceutical giant Novo Nordisk and said it is exploring selling parts of the data after unsuccessfully demanding $25 million from the company.
